BiotechTube

Telbivudine/LDT600A

ApprovedWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Compensated Chronic Hepatitis B

Conditions

Compensated Chronic Hepatitis B

Trial Timeline

Apr 1, 2009 → Apr 1, 2011

NCT ID
NCT00862706

About Telbivudine/LDT600A

Telbivudine/LDT600A is a approved stage product being developed by Novartis for Compensated Chronic Hepatitis B. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00862706. Target conditions include Compensated Chronic Hepatitis B.

What happened to similar drugs?

2 of 4 similar drugs in Compensated Chronic Hepatitis B were approved

Approved (2) Terminated (0) Active (2)
✅Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
✅telbivudine/LDT600NovartisApproved
🔄Aliskiren + PlaceboNovartisPhase 3
🔄Albutein 20%GrifolsPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00862706ApprovedWithdrawn

Competing Products

9 competing products in Compensated Chronic Hepatitis B

See all competitors
ProductCompanyStageHype Score
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
Mesenchymal Stem CellRohto PharmaceuticalPre-clinical
26
Mesenchymal stem cellRohto PharmaceuticalPhase 1/2
32
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
39
telbivudine/LDT600NovartisApproved
43
Terlipressin acetate + Serelaxin (RLX030)NovartisPhase 2
35
Aliskiren + PlaceboNovartisPhase 3
40
BMS-986259Bristol Myers SquibbPhase 2
35
Albutein 20%GrifolsPhase 3
37